Brevan Howard Capital Management LP Phathom Pharmaceuticals, Inc. Transaction History
Brevan Howard Capital Management LP
- $11 Billion
- Q2 2024
A detailed history of Brevan Howard Capital Management LP transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 18,792 shares of PHAT stock, worth $339,759. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,792Holding current value
$339,759% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PHAT
# of Institutions
123Shares Held
59MCall Options Held
467KPut Options Held
34.9K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$183 Million6.14% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$135 Million27.45% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$63.2 Million4.3% of portfolio
-
Invesco Ltd. Atlanta, GA3.14MShares$56.8 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$52.9 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $708M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...